Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Issue published November 1, 2000 Previous issue | Next issue

  • Volume 106, Issue 9
Go to section:
  • In this issue
  • Perspectives
  • Commentary
  • Research Articles
In this issue
In This Issue
John Ashkenas
John Ashkenas
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1063-1063. https://doi.org/10.1172/JCI119913.
View: Text | PDF

In This Issue

  • Text
  • PDF
Abstract

Authors

John Ashkenas

×
Perspectives
RNA-transfected dendritic cells in cancer immunotherapy
Duane A. Mitchell, Smita K. Nair
Duane A. Mitchell, Smita K. Nair
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1065-1069. https://doi.org/10.1172/JCI11405.
View: Text | PDF

RNA-transfected dendritic cells in cancer immunotherapy

  • Text
  • PDF
Abstract

Authors

Duane A. Mitchell, Smita K. Nair

×

Therapeutic applications of transcription factor decoy oligonucleotides
Michael J. Mann, Victor J. Dzau
Michael J. Mann, Victor J. Dzau
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1071-1075. https://doi.org/10.1172/JCI11459.
View: Text | PDF

Therapeutic applications of transcription factor decoy oligonucleotides

  • Text
  • PDF
Abstract

Authors

Michael J. Mann, Victor J. Dzau

×
Commentary
LRP in Alzheimer’s disease: friend or foe?
Paula G. Ulery, Dudley K. Strickland
Paula G. Ulery, Dudley K. Strickland
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1077-1079. https://doi.org/10.1172/JCI11455.
View: Text | PDF

LRP in Alzheimer’s disease: friend or foe?

  • Text
  • PDF
Abstract

Authors

Paula G. Ulery, Dudley K. Strickland

×
Research Articles
Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase– and cathepsin-dependent emphysema
Tao Zheng, … , Steven D. Shapiro, Jack A. Elias
Tao Zheng, … , Steven D. Shapiro, Jack A. Elias
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1081-1093. https://doi.org/10.1172/JCI10458.
View: Text | PDF

Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase– and cathepsin-dependent emphysema

  • Text
  • PDF
Abstract

Cigarette smoke exposure is the major cause of chronic obstructive pulmonary disease (COPD). However, only a minority of smokers develop significant COPD, and patients with asthma or asthma-like airway hyperresponsiveness or eosinophilia experience accelerated loss of lung function after cigarette smoke exposure. Pulmonary inflammation is a characteristic feature of lungs from patients with COPD. Surprisingly, the mediators of this inflammation and their contributions to the pathogenesis and varied natural history of COPD are not well defined. Here we show that IL-13, a critical cytokine in asthma, causes emphysema with enhanced lung volumes and compliance, mucus metaplasia, and inflammation, when inducibly overexpressed in the adult murine lung. MMP-2, -9, -12, -13, and -14 and cathepsins B, S, L, H, and K were induced by IL-13 in this setting. In addition, treatment with MMP or cysteine proteinase antagonists significantly decreased the emphysema and inflammation, but not the mucus in these animals. These studies demonstrate that IL-13 is a potent stimulator of MMP and cathepsin-based proteolytic pathways in the lung. They also demonstrate that IL-13 causes emphysema via a MMP- and cathepsin-dependent mechanism(s) and highlight common mechanisms that may underlie COPD and asthma.

Authors

Tao Zheng, Zhou Zhu, Zhongde Wang, Robert J. Homer, Bing Ma, Richard J. Riese Jr., Harold A. Chapman Jr., Steven D. Shapiro, Jack A. Elias

×

Bone homeostasis in growth hormone receptor–null mice is restored by IGF-I but independent of Stat5
Natalie A. Sims, … , Roland Baron, Paul A. Kelly
Natalie A. Sims, … , Roland Baron, Paul A. Kelly
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1095-1103. https://doi.org/10.1172/JCI10753.
View: Text | PDF

Bone homeostasis in growth hormone receptor–null mice is restored by IGF-I but independent of Stat5

  • Text
  • PDF
Abstract

Growth hormone (GH) regulates both bone growth and remodeling, but it is unclear whether these actions are mediated directly by the GH receptor (GHR) and/or IGF-I signaling. The actions of GH are transduced by the Jak/Stat signaling pathway via Stat5, which is thought to regulate IGF-I expression. To determine the respective roles of GHR and IGF-I in bone growth and remodeling, we examined bones of wild-type, GHR knockout (GHR–/–), Stat5ab–/–, and GHR–/– mice treated with IGF-I. Reduced bone growth in GHR–/– mice, due to a premature reduction in chondrocyte proliferation and cortical bone growth, was detected after 2 weeks of age. Additionally, although trabecular bone volume was unchanged, bone turnover was significantly reduced in GHR–/– mice, indicating GH involvement in the high bone-turnover level during growth. IGF-I treatment almost completely rescued all effects of the GHR–/– on both bone growth and remodeling, supporting a direct effect of IGF-I on both osteoblasts and chondrocytes. Whereas bone length was reduced in Stat5ab–/– mice, there was no reduction in trabecular bone remodeling or growth-plate width as observed in GHR–/– mice, indicating that the effects of GH in bone may not involve Stat5 activation.

Authors

Natalie A. Sims, Philippe Clément-Lacroix, Francesca Da Ponte, Yasmina Bouali, Nadine Binart, Richard Moriggl, Vincent Goffin, Karen Coschigano, Martine Gaillard-Kelly, John Kopchick, Roland Baron, Paul A. Kelly

×

Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis
Lea McLaughlin, … , Judith A.K. Harmony, Bruce J. Aronow
Lea McLaughlin, … , Judith A.K. Harmony, Bruce J. Aronow
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1105-1113. https://doi.org/10.1172/JCI9037.
View: Text | PDF

Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis

  • Text
  • PDF
Abstract

Apolipoprotein J/clusterin (apoJ/clusterin), an intriguing protein with unknown function, is induced in myocarditis and numerous other inflammatory injuries. To test its ability to modify myosin-induced autoimmune myocarditis, we generated apoJ-deficient mice. ApoJ-deficient and wild-type mice exhibited similar initial onset of myocarditis, as evidenced by the induction of two early markers of the T cell–mediated immune response, MHC-II and TNF receptor p55. Furthermore, autoantibodies against the primary antigen cardiac myosin were induced to the same extent. Although the same proportion of challenged animals exhibited some degree of inflammatory infiltrate, inflammation was more severe in apoJ-deficient animals. Inflammatory lesions were more diffuse and extensive in apoJ-deficient mice, particularly in females. In marked contrast to wild-type animals, the development of a strong generalized secondary response against cardiac antigens in apoJ-deficient mice was predictive of severe myocarditis. Wild-type mice with a strong Ab response to secondary antigens appeared to be protected from severe inflammation. After resolution of inflammation, apoJ-deficient, but not wild-type, mice exhibited cardiac function impairment and severe myocardial scarring. These results suggest that apoJ limits progression of autoimmune myocarditis and protects the heart from postinflammatory tissue destruction.

Authors

Lea McLaughlin, Guang Zhu, Meenakshi Mistry, Cathy Ley-Ebert, William D. Stuart, Carolyn J. Florio, Pamela A. Groen, Sandra A. Witt, Thomas R. Kimball, David P. Witte, Judith A.K. Harmony, Bruce J. Aronow

×

Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells
Richard Bouley, … , Dennis A. Ausiello, Dennis Brown
Richard Bouley, … , Dennis A. Ausiello, Dennis Brown
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1115-1126. https://doi.org/10.1172/JCI9594.
View: Text | PDF

Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells

  • Text
  • PDF
Abstract

In collecting duct principal cells, aquaporin 2 (AQP2) is shuttled from intracellular vesicles to the plasma membrane upon vasopressin (VP) stimulation. VP activates adenylyl cyclase, increases intracellular cAMP, activating protein kinase A (PKA) to phosphorylate AQP2 on the COOH-terminal residue, serine 256. Using rat kidney slices and LLC-PK1 cells stably expressing AQP2 (LLC-AQP2 cells), we now show that AQP2 trafficking can be stimulated by cAMP-independent pathways. In these systems, the nitric oxide (NO) donors sodium nitroprusside (SNP) and NONOate and the NO synthase substrate L-arginine mimicked the effect of VP, stimulating relocation of AQP2 from cytoplasmic vesicles to the plasma membrane. Unlike VP, these other agents did not increase intracellular cAMP. However, SNP increased intracellular cGMP, and exogenous cGMP stimulated AQP2-membrane insertion. Atrial natriuretic factor, which signals via cGMP, also stimulated AQP2 translocation. The VP and SNP effects were blocked by the kinase inhibitor H89. SNP did not stimulate membrane insertion of AQP2 in LLC-PK1 cells expressing the phosphorylation-deficient mutant 256SerAla-AQP2, indicating that phosphorylation of Ser256 is required for signaling. Both PKA and cGMP-dependent protein kinase G phosphorylated AQP2 on this COOH-terminal residue in vitro. These results demonstrate a novel, cAMP-independent and cGMP-dependent pathway for AQP2 membrane insertion in renal epithelial cells.

Authors

Richard Bouley, Sylvie Breton, Tian-xiao Sun, Margaret McLaughlin, Ndona N. Nsumu, Herbert Y. Lin, Dennis A. Ausiello, Dennis Brown

×

Cathepsin B contributes to TNF-α–mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c
M. Eugenia Guicciardi, … , Scott H. Kaufmann, Gregory J. Gores
M. Eugenia Guicciardi, … , Scott H. Kaufmann, Gregory J. Gores
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1127-1137. https://doi.org/10.1172/JCI9914.
View: Text | PDF

Cathepsin B contributes to TNF-α–mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c

  • Text
  • PDF
Abstract

TNF-α–induced apoptosis is thought to involve mediators from acidic vesicles. Cathepsin B (cat B), a lysosomal cysteine protease, has recently been implicated in apoptosis. To determine whether cat B contributes to TNF-α–induced apoptosis, we exposed mouse hepatocytes to the cytokine in vitro and in vivo. Isolated hepatocytes treated with TNF-α in the presence of the transcription inhibitor actinomycin D (AcD) accumulated cat B in their cytosol. Further experiments using cell-free systems indicated that caspase-8 caused release of active cat B from purified lysosomes and that cat B, in turn, increased cytosol-induced release of cytochrome c from mitochondria. Consistent with these observations, the ability of TNF-α/AcD to induce mitochondrial release of cytochrome c, caspase activation, and apoptosis of isolated hepatocytes was markedly diminished in cells from CatB–/– mice. Deletion of the CatB gene resulted in diminished liver injury and enhanced survival after treatment in vivo with TNF-α and an adenovirus construct expressing the IκB superrepressor. Collectively, these observations suggest that caspase-mediated release of cat B from lysosomes enhances mitochondrial release of cytochrome c and subsequent caspase activation in TNF-α–treated hepatocytes.

Authors

M. Eugenia Guicciardi, Jan Deussing, Hideyuki Miyoshi, Steven F. Bronk, Phyllis A. Svingen, Christoph Peters, Scott H. Kaufmann, Gregory J. Gores

×

Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury
Christopher P. Regan, … , Cort S. Madsen, Gary K. Owens
Christopher P. Regan, … , Cort S. Madsen, Gary K. Owens
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1139-1147. https://doi.org/10.1172/JCI10522.
View: Text | PDF

Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury

  • Text
  • PDF
Abstract

While it is well established that phenotypic modulation of vascular smooth muscle cells (VSMCs) contributes to the development and progression of vascular lesions, little is known regarding the molecular mechanisms of phenotypic modulation in vivo. Here we show that vascular injury reduces transcription of VSMC differentiation marker genes, and we identify cis regulatory elements that may mediate this decrease. Using a carotid wire-injury model in mice carrying transgenes for smooth muscle α-actin, smooth muscle myosin heavy chain, or a SM22α promoter–β-gal reporter, we collected arteries 7 and 14 days after injury and assessed changes in endogenous protein and mRNA levels and in β-gal activity. Endogenous levels for all markers were decreased 7 days after injury and returned to nearly control levels by 14 days. β-gal staining in all lines followed a similar pattern, suggesting that transcriptional downregulation contributed to the injury-induced decreases. To begin to dissect this response, we mutated a putative G/C-rich repressor in the SM22α promoter transgene and found that this mutation significantly attenuated injury-induced downregulation. Hence, transcriptional downregulation contributes to injury-induced decreases in VSMC differentiation markers, an effect that may be partially mediated through a G/C-rich repressor element.

Authors

Christopher P. Regan, Paul J. Adam, Cort S. Madsen, Gary K. Owens

×

Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase–deficient fetal thymic organ cultures
Linda F. Thompson, … , Michael S. Hershfield, Regina Resta
Linda F. Thompson, … , Michael S. Hershfield, Regina Resta
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1149-1157. https://doi.org/10.1172/JCI9944.
View: Text | PDF

Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase–deficient fetal thymic organ cultures

  • Text
  • PDF
Abstract

Murine fetal thymic organ culture was used to investigate the mechanism by which adenosine deaminase (ADA) deficiency causes T-cell immunodeficiency. C57BL/6 fetal thymuses treated with the specific ADA inhibitor 2′-deoxycoformycin exhibited features of the human disease, including accumulation of dATP and inhibition of S-adenosylhomocysteine hydrolase enzyme activity. Although T-cell receptor (TCR) Vβ gene rearrangements and pre–TCR-α expression were normal in ADA-deficient cultures, the production of αβ TCR+ thymocytes was inhibited by 95%, and differentiation was blocked beginning at the time of β selection. In contrast, the production of γδ TCR+ thymocytes was unaffected. Similar results were obtained using fetal thymuses from ADA gene-targeted mice. Differentiation and proliferation were preserved by the introduction of a bcl-2 transgene or disruption of the gene encoding apoptotic protease activating factor–1. The pan-caspase inhibitor carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone also significantly lessened the effects of ADA deficiency and prevented the accumulation of dATP. Thus, ADA substrates accumulate and disrupt thymocyte development in ADA deficiency. These substrates derive from thymocytes that undergo apoptosis as a consequence of failing to pass developmental checkpoints, such as β selection.

Authors

Linda F. Thompson, C. Justin Van De Wiele, Aletha B. Laurent, Scott W. Hooker, James G. Vaughn, Hong Jiang, Kamayani Khare, Rodney E. Kellems, Michael R. Blackburn, Michael S. Hershfield, Regina Resta

×

Modulation of amyloid β-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor–related protein pathway
David E. Kang, … , Robert Katzman, Edward H. Koo
David E. Kang, … , Robert Katzman, Edward H. Koo
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1159-1166. https://doi.org/10.1172/JCI11013.
View: Text | PDF

Modulation of amyloid β-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor–related protein pathway

  • Text
  • PDF
Abstract

Susceptibility to Alzheimer’s disease (AD) is governed by multiple genetic factors. Remarkably, the LDL receptor–related protein (LRP) and its ligands, apoE and α2M, are all genetically associated with AD. In this study, we provide evidence for the involvement of the LRP pathway in amyloid deposition through sequestration and removal of soluble amyloid β-protein (Aβ). We demonstrate in vitro that LRP mediates the clearance of both Aβ40 and Aβ42 through a bona fide receptor-mediated uptake mechanism. In vivo, reduced LRP expression is associated with LRP genotypes and is correlated with enhanced soluble Aβ levels and amyloid deposition. Although LRP has been proposed to be a clearance pathway for Aβ, this work provides the first in vivo evidence that the LRP pathway may modulate Aβ deposition and AD susceptibility by regulating the removal of soluble Aβ.

Authors

David E. Kang, Claus U. Pietrzik, Larry Baum, Nathalie Chevallier, David E. Merriam, Maria Z. Kounnas, Steven L. Wagner, Juan C. Troncoso, Claudia H. Kawas, Robert Katzman, Edward H. Koo

×

A GNAS1 imprinting defect in pseudohypoparathyroidism type IB
Jie Liu, … , Leslie G. Biesecker, Lee S. Weinstein
Jie Liu, … , Leslie G. Biesecker, Lee S. Weinstein
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1167-1174. https://doi.org/10.1172/JCI10431.
View: Text | PDF

A GNAS1 imprinting defect in pseudohypoparathyroidism type IB

  • Text
  • PDF
Abstract

Pseudohypoparathyroidism type IB (PHPIB) is characterized by renal resistance to parathyroid hormone (PTH) and the absence of other endocrine or physical abnormalities. Familial PHPIB has been mapped to 20q13, near GNAS1, which encodes Gsα, the G protein α-subunit required for receptor-stimulated cAMP generation. However, Gsα function is normal in blood cells from PHPIB patients, ruling out mutations within the Gsα coding region. In mice Gsα is expressed only from the maternal allele in renal proximal tubules (the site of PTH action) but is biallelically expressed in most other tissues. Studies in patients with Albright hereditary osteodystrophy suggest a similar Gsα imprinting pattern in humans. Here we identify a region upstream of the Gsα promoter that is normally methylated on the maternal allele and unmethylated on the paternal allele, but that is unmethylated on both alleles in all 13 PHPIB patients studied. Within this region is an alternative promoter and first exon (exon 1A), generating transcripts that are normally expressed only from the paternal allele, but that are biallelically expressed in PHPIB patients. Therefore, PHPIB is associated with a paternal-specific imprinting pattern of the exon 1A region on both alleles, which may lead to decreased Gsα expression in renal proximal tubules. We propose that loss of exon 1A imprinting is the cause of PHPIB.

Authors

Jie Liu, Deborah Litman, Marjorie J. Rosenberg, Shuhua Yu, Leslie G. Biesecker, Lee S. Weinstein

×

The bile acid synthetic gene 3β-hydroxy-Δ5-C27-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis
Margrit Schwarz, … , Ingemar Björkhem, David W. Russell
Margrit Schwarz, … , Ingemar Björkhem, David W. Russell
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1175-1184. https://doi.org/10.1172/JCI10902.
View: Text | PDF

The bile acid synthetic gene 3β-hydroxy-Δ5-C27-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis

  • Text
  • PDF
Abstract

We used expression cloning to isolate cDNAs encoding a microsomal 3β-hydroxy-Δ5-C27-steroid oxidoreductase (C27 3β-HSD) that is expressed predominantly in the liver. The predicted product shares 34% sequence identity with the C19 and C21 3β-HSD enzymes, which participate in steroid hormone metabolism. When transfected into cultured cells, the cloned C27 3β-HSD cDNA encodes an enzyme that is active against four 7α-hydroxylated sterols, indicating that a single C27 3β-HSD enzyme can participate in all known pathways of bile acid synthesis. The expressed enzyme did not metabolize several different C19/21 steroids as substrates. The levels of hepatic C27 3β-HSD mRNA in the mouse are not sexually dimorphic and do not change in response to dietary cholesterol or to changes in bile acid pool size. The corresponding human gene on chromosome 16p11.2-12 contains six exons and spans 3 kb of DNA, and we identified a 2-bp deletion in the C27 3β-HSD gene of a patient with neonatal progressive intrahepatic cholestasis. This mutation eliminates the activity of the enzyme in transfected cells. These findings establish the central role of C27 3β-HSD in the biosynthesis of bile acids and provide molecular tools for the diagnosis of a third type of neonatal progressive intrahepatic cholestasis associated with impaired bile acid synthesis.

Authors

Margrit Schwarz, Angelique C. Wright, Daphne L. Davis, Hisham Nazer, Ingemar Björkhem, David W. Russell

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts